Author: Dr. Florian Stieglitz, Market Access Consultant

Germany’s statutory health insurers (GKV) face mounting deficits, now compounded by surging expenditures on advanced therapies. The 2025 report of the German Advisory Council on Health and Care (Sachverständigenrat Gesundheit & Pflege, SVR), titled “Preise innovativer Arzneimittel in einem lernenden Gesundheitssystem,” offers a blueprint for reforming AMNOG and pharmaceutical pricing. While its goal—safeguarding sustainable financing amid spiralling drug costs—is laudable, the SVR’s recommendations introduce far-reaching uncertainties for manufacturers that demand immediate strategic attention. 

From “One-Shot” to “Learning” Pricing 

Since 2011, AMNOG has been defined by a single early benefit assessment and reimbursement negotiations. The SVR observes that this “front-loaded” model cannot keep pace with one-off gene therapies and orphan drugs commanding list prices of up to €2 million per treatment. It therefore proposes transforming Germany’s pricing system into a truly learning health system, where: 

• The abolition of the orphan drug privilege: Currently, orphan drugs are granted a “fictive” added benefit upon market entry. The SVR proposes to eliminate this status and subject all new medicines—regardless of their orphan designation—to a full benefit assessment against an appropriate comparator (ACT) from the start. 

• Routine cost-effectiveness assessment (CEA): Until now, CEAs have been used only selectively in Germany. The SVR now recommends that they become a standard component of price negotiations utilising a cross-indication unit of measurement based on a defined selection of medicinal products. This would create comparability of price premiums for units of added benefit across indications. 

• Dynamic pricing through budget caps: A particularly controversial suggestion is the introduction of an overall pharmaceutical budget, mirroring frameworks in Spain and Italy. Once exceeded, this cap would automatically trigger price reductions, such as a percentage discount on the reimbursement prices of all budget-relevant patented medicines, this reduction could be carried out on a global, regional or indication specific level. 

• Mandatory reevaluations and price renegotiations: The SVR recommends implementing a system of ongoing benefit reassessments, which could lead to additional post-launch price reductions. Manufacturers would be expected to deliver new evidence, with price renegotiations becoming a regular recurring part of the product lifecycle.  

• Elimination of the initial free pricing window: The report proposes the introduction of an externally defined interim price based on comparator therapy costs. This interim price would apply from market entry until a final price is negotiated, reducing manufacturers’ flexibility and leverage during the early access period. 

• Strengthening the negotiating power of the GKV-SV: To level out ‘asymmetries’ in price negotiations between pharmaceutical companies and the GKV-SV, the SVR proposes that the GKV-SV should also be granted the right to withdraw from price negotiations and thus from reimbursement. In addition, similar to Belgium or the Netherlands, active substance tenders should be made possible for therapeutic areas, so that only one active substance from a set of equivalent active substances in the therapeutic areas is reimbursable and leading to a bidding war between the manufactures. 

Stakeholder Reactions 

• Health Minister Nina Warken acknowledged the report’s “valuable insights” but cautioned that “We must always find the right balance in the pricing of innovative medicines. On the one hand, we must provide people with rapid access to new medicines and at the same time strengthen Germany as a centre for pharmaceuticals. On the other hand, we must keep a close eye on price trends”. 

• The VFA (Association of Research-Based Pharmaceutical Companies) warned that a “drastic tightening of the handling of rare diseases would lead to a massive jeopardisation of care in a particularly sensitive area.” 

• The GKV-SV welcomed the focus on financial viability: “In view of the financial situation of the statutory health insurance system, we need new structural and effective approaches for the price control of patent medicines depending on their authorisation status, such as a collective limitation of pharmaceutical expenditure.” 

A Call for Strategic Partnership 

The SVR’s vision of a “learning healthcare system” demands unprecedented agility from manufacturers: 

• Dynamic pricing models must be stress-tested against real-world usage scenarios. 

• HEOR infrastructures require expansion from launch dossiers to ongoing registries, adaptive trials, and longitudinal patient-reported outcomes. 

• Market-access strategies must anticipate interim pricing, periodic renegotiations, and nationwide budget triggers. 

At Kintiga, we have guided clients through every evolution of AMNOG since its inception, leveraging deep AMNOG know-how, advanced HEOR teams, and insights from UK NICE, Benelux HTA pilots, and beyond.  

The bottom line: If implemented, the SVR’s 2025 recommendations define a pivotal shift toward continuous learning, automated budget discipline, and ever-closer coupling of evidence to reward. For pharmaceutical and biotech companies committed to patient access and sustainable innovation in Germany, inaction is not an option. Engaging strategic, HEOR-savvy partners like Kintiga today will turn uncertainty into a competitive advantage—and ensure that your products thrive in this possible new era. 

Sources:  

SVR report (press release): Pressemitteilung_und_Executive_Summary_zum_SVR-Gutachten_2025.pdf 

SVR report (long version): Gutachten SVR 2025 – Preise innovativer Arzneimittel in einem lernenden Gesundheitssystem 

Tagesspiegel: Sachverständige plädieren für Pharma-Sparkurs – Tagesspiegel Background 

Ärzteblatt: Sachverständige legen Maßnahmenpaket zur Dämpfung der Arzneimittelausgaben vor – News – Deutsches Ärzteblatt